Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of tafamidis in transthyretin amyloid cardiomyopathy
2016-000868-42Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and amyloid cardiomyopathy (2 arms), sponsored by Pfizer. Primary endpoint: Long-term safety of tafamidis meglumine. Started Jul 2016; status: active.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2016-000868-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000868-42.